Karyopharm Therapeutics' (KPTI) Outperform Rating Reiterated at Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report)'s stock had its "outperform" rating reiterated by Royal Bank of Canada in a report issued on Thursday,Benzinga reports. They currently have a $3.00 price target on the stock. Royal Bank of Canada's price target would indicate a potential upside of 401.34% from the stock's previous close.

Several other equities analysts have also weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday. Piper Sandler upped their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $5.00.

Karyopharm Therapeutics Stock Performance

Shares of KPTI stock traded down $0.01 during mid-day trading on Thursday, hitting $0.60. The company's stock had a trading volume of 1,057,547 shares, compared to its average volume of 787,132. Karyopharm Therapeutics has a 52 week low of $0.53 and a 52 week high of $1.70. The company's fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.76. The company has a market cap of $75.54 million, a PE ratio of -0.59 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in Karyopharm Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock worth $1,125,000 after buying an additional 43,856 shares in the last quarter. GSA Capital Partners LLP raised its holdings in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after purchasing an additional 792,283 shares during the last quarter. FMR LLC lifted its position in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company's stock valued at $307,000 after purchasing an additional 76,510 shares in the last quarter. Jane Street Group LLC boosted its holdings in Karyopharm Therapeutics by 265.5% during the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock worth $506,000 after purchasing an additional 543,556 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in Karyopharm Therapeutics in the 4th quarter worth about $31,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).